UniCredit Bonus Zert GIS 22.08.20.../ DE000HVB8305 /
28/06/2024 19:36:55 | Chg.-1.070 | Bid19:57:54 | Ask19:57:54 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
912.080USD | -0.12% | 911.660 Bid Size: 50 |
920.820 Ask Size: 50 |
GILEAD SCIENCES DL... | - - | 22/08/2028 | Call |
GlobeNewswire
28/06
Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease
GlobeNewswire
26/06
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
GlobeNewswire
26/06
Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors
GlobeNewswire
18/06
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation C...
GlobeNewswire
10/06
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus He...
GlobeNewswire
22/05
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congres...
GlobeNewswire
14/05
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
GlobeNewswire
09/05
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim ...
GlobeNewswire
09/05
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
08/05
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
GlobeNewswire
08/05
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
GlobeNewswire
29/04
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...
GlobeNewswire
19/04
ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies...
GlobeNewswire
10/04
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...
GlobeNewswire
02/04
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
GlobeNewswire
01/04
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Fin...
GlobeNewswire
28/03
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlight...
GlobeNewswire
28/03
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program